Analysts’ Top Healthcare Picks: BOLD, MGEN

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Audentes Therapeutics (NASDAQ: BOLD) and Miragen Therapeutics Inc (NASDAQ: MGEN) with bullish sentiments.

Audentes Therapeutics (NASDAQ: BOLD)

William Blair analyst Raju Prasad maintained a Buy rating on Audentes Therapeutics (NASDAQ: BOLD) today. The company’s shares closed yesterday at $33.95.

Prasad wrote:

“We view the update as a positive and initial safety concerns as largely overblown, particularly when compared with the data from the INCEPTUS run-in study and noting that the majority were in a single patient who had previously experienced several pneumonia episodes, a tachycardic event in the run-in trial, and was on 24 hours of invasive ventilation at baseline.”

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 24.1% and a 66.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Spark Therapeutics, and PTC Therapeutics.

Currently, the analyst consensus on Audentes Therapeutics is Moderate Buy and the average price target is $36, representing a 6.0% upside.

In a report issued on May 10, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Miragen Therapeutics Inc (NASDAQ: MGEN)

Oppenheimer analyst Leah R. Cann maintained a Buy rating on Miragen Therapeutics Inc (NASDAQ: MGEN) today and set a price target of $13. The company’s shares closed yesterday at $7.51.

Cann wrote:

“MiRagen reported it will present new data for cobomarsen (MRG-106) at the in June. miRagen has a pipeline of two experimental clinical therapies. The first anticipated commercial impact is from MRG-106 in 2022. The data released yesterday, along with the planned phase II trial design support our expectation that MRG-106 will be able to proceed to a registration phase II study, avoiding phase III trials. We estimate that MiRagen’s operating losses will continue until the launch of MRG-106 in 2022, when we estimate the company will turn profitable as revenue starts to meaningfully offset losses.”

According to TipRanks.com, Cann is a 5-star analyst with an average return of 15.8% and a 58.6% success rate. Cann covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics Inc, Crispr Therapeutics AG, and Intellia Therapeutics.

Currently, the analyst consensus on Miragen Therapeutics Inc is Strong Buy and the average price target is $16.90, representing a 125.0% upside.

In a report issued on May 10, B.Riley FBR also reiterated a Buy rating on the stock with a $18.50 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.